What You Should Know
- Healthcare intelligence leader ConcertAI has unveiled major AI-driven enhancements to its CancerLinQ Suite at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Powered by Cara, ConcertAI’s proprietary agentic AI platform, the suite automatically parses structured and unstructured data on a weekly basis across a massive footprint of 13 million patient records.
- The upgraded TriaLinQ module automates patient screening for complex biomarkers and lines of therapy, screening eligible patients 3.3 times faster than manual methods and boosting trial enrollment by up to 50%.
- The PatientLinQ module maps a 360-degree view of patient care, automatically identifying clinical trials where a patient has a 90% or greater likelihood of eligibility based on longitudinal real-world data.
- The system-wide architecture integrates directly into native clinician workflows across more than 900 active sites of care to eliminate point-of-care data fragmentation and close critical care testing gaps.
The modern oncology care team operates within a punishing, data-dense clinical paradigm. The velocity of oncology innovation has accelerated exponentially, flooding the sector with novel genomic biomarkers, rapidly expanding lines of targeted therapy, and a complex, highly distributed clinical trial ecosystem. Yet, while the therapeutic options available to fight cancer have multiplied, the frontline software systems used to manage this information have remained stubbornly passive. Doctors are forced to make high-stakes, life-altering treatment decisions during tightly constrained, brief patient encounters, manually sorting through mountains of unstructured clinic notes, pathology reports, and external electronic health record (EHR) files.
When data remains trapped in uncurated formats, the clinical fallout is immediate. Eligible patients are routinely missed for leading-edge clinical trials, critical gaps in biomarker testing go unnoticed, and physicians lack the real-world cohort data necessary to confidently evaluate standard treatment outcomes at the bedside. For enterprise cancer centers, this technical fragmentation slows trial enrollment velocity, increases administrative charting burdens, and compromises patient longevity.
To convert this massive lake of unstructured medical text into a continuous system of clinical action, real-world healthcare intelligence pioneer ConcertAI has unveiled major, clinically intelligent advancements to its CancerLinQ Suite. Formally announced at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the upgrades embed automated trial matching, cohort comparisons, and real-time quality benchmarking directly within the clinician’s native workflow.
Automating the Triage Engine: 3.3x Faster Trial Screening
ConcertAI’s updated architecture addresses the point-of-care bottleneck by shifting clinical data processing from a monthly or quarterly batch review into an automated weekly routine. The engine driving this continuous curation is Cara, ConcertAI’s proprietary agentic AI platform. Engineered explicitly for complex oncology use cases, Cara reads and reasons across a highly secure dataset encompassing more than 13 million patient records across all 50 states, sourcing deep longitudinal data from over 900 distinct sites of care.
This underlying intelligence layer actively powers two core clinical modules inside the provider workflow:
- The TriaLinQ Module: This workflow-integrated module automates the historically manual patient eligibility screening pipeline. By deploying advanced AI models trained to instantly pinpoint specific eligibility determinants—such as distinct biomarker variations, historical lines of therapy, localized cancer progression, and disease recurrence—the platform screens eligible patients 3.3 times faster than traditional manual data abstraction. This rapid triage supports up to a 50% increase in clinical trial enrollment, expanding critical patient access to cutting-edge protocols.
- The PatientLinQ Module: Built to deliver an exhaustive, 360-degree view of the patient journey, this module specializes in surfacing targeted clinical trials where a patient carries a 90% or greater likelihood of structural eligibility. It automatically maps these opportunities against the patient’s exact clinical context, allowing oncologists to instantly compare individual charts against macro real-world cohorts to accurately gauge treatment safety and overall survival outcomes.
Shaalan Beg, M.D., Chief Medical Officer of Oncology at ConcertAI, emphasized that the true validation of oncology technology does not reside in platform complexity, but in whether the software actively protects the clinician at the bedside. By putting real-time cohort comparisons and precise trial matches directly into active care workflows, the CancerLinQ updates deliver an automated asset that actively informs treatment decisions during the critical moments that matter most.
